Parexel announced the opening of its new European Coordination Hub and Distribution Center in Berlin-Sch?nefeld.
Parexel announced the opening of its new European Coordination Hub and Distribution Center in Berlin-Schönefeld, Germany. Its capabilities include synchronized coordination of clinical trial supplies, ancillary supplies and central laboratory services and features more than 65,000 cubic meters of storage space. It offers lab-kit assembly and provides storage and distribution of ancillary materials.
The new European Coordination Hub and Distribution Center will be licensed to store Investigational Medicinal Products (IMPs) and Non-Investigational Medicinal Products (N-IMPs). It will also offer secondary packaging, re-labeling, and compliance with Good Distribution Practice (GDP) of medical devices and ambient, refrigerated and frozen medicinal products, including controlled substances. On-site Qualified Person (QP), Quality Control (QC) and production personnel will manage regulatory-compliance requirements. They will also streamline product import, receipt, storage, packaging and labeling, release, shipment, return and destruction timelines.
PAREXEL also is opening new full-service clinical trial supply depots in Buenos Aires, Argentina, and São Paulo, Brazil. The facilities are part of PAREXEL’s growing global system of more than 50 owned or in-network depots and three regional distribution centers.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.